# Article: Preserve Incentives ...
### Introduction      
药物涨价很快，以前的很多观点认为，是由于进入壁垒和防止低价的活动仿制药(Generic Drugs)上市（延长专利和非专利独占权exclutivities）      
本文重点关注仿制药获得专利和批准后发生的更令人不安的市场活动部分: Drug distribution, Drug ownership, manipulation, reimbursement schemes           
为什么药价固执地(Stubbornly)继续上涨？因为系统的内部激励，在系统中存在高度保密和高度集中的行业，称为药房福利经理（PBM）这些中间参与者在品牌制药公司和支付账单的公司之间协商价格，安排各种制药公司提供的的rebate。他们还建立了 The formularies, schedules that set the terms on which patients can access particular drugs and the reimbursement rates patients will get.      
这也使得新的出廉价替代药品公司不能 gain a foothold （站稳脚跟）      
最终，整个系统使得consumer 和 customer 受害      


### The Landscape      
This section explains the way in which the general health care market is an imperfect market and that, even in the context of such market imperfections, spending on drugs defies rationality. Finally,this section introduces the Pharmacy Benefit Manager, a main actor in thehealth care space and one who plays a key role in rising prices.           

##### Branded Prescription Drugs      

##### Rebates and Reimbursement: The Byzantine World of Drug Sales           


###  How the Incentive Structures Drive Prices Higher          

##### Why PBMs May Prefer Higher Prices         

##### Why Pharmacies May Prefer Higher Prices           

##### Why Insures May be Pushed Towards Higher-Priced Drugs            

##### Doctors, Hispitals, and Other Medical Practitioners           

##### Patients and Patient Advocacy Groups                

##### The Full Landscape                 

### Alligning Incentives                 


##### What Won't Work          


##### What will work ?            


### Conclusion
